Search

What can I expect?

Learning objectives


Discuss the principles of translational research design and execution. Recognize the ethical and regulatory issues of translational research. Examine the fundamentals of competitive grant writing, abstract presentation, and manuscript preparation.

Read more

What can I expect?

Learning Objectives
To have a greater understanding of computational techniques as applied to haematological datasets,
To improve personal computational biology skillset, tailored to the project,
To further develop and widen your network of potential collaborators, both in terms of peer group and…

Read more

Meet Robert Hills, our August volunteer of the month

Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.

Read more

Meet Robert Hills, our August volunteer of the month

Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

EHA Bilateral Collaborative Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more